Early clinical and pharmacokinetic results of lower dose fludarabine and cyclophosphamide, and high dose rituximab (FCR-Lite) for patients with untreated chronic lymphocytic leukemia (CLL).

被引：2
|
作者：
Tarhini, Ahmad A. [1 ]
Land, S. [1 ]
Meisner, D. [1 ]
Pietragallo, L. [1 ]
Sulecki, M. [1 ]
Lim, F. [1 ]
Kiefer, Gauri J. [1 ]
Pinkerton, R. [1 ]
Obsom, J. [1 ]
Sukaly, S. [1 ]
Schaefer, P. M. [1 ]
Foon, Kenneth A. [1 ]
机构：
[1] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2844.2844
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2844
引用
收藏
页码：805A / 805A
页数：1
相关论文
共 50 条
  • [31] Interim results of the combination rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) followed by rituximab maintenance in previously untreated chronic lymphocytic leukemia (CLL)
    Bosch, F.
    Muntanola, A.
    Villamor, N.
    Terol, M.
    Gonzalez-Barca, E.
    Ribera, J.
    Gonzalez, M.
    Abella, E.
    Delgado, J.
    Carbonell, F.
    Marco, J. Garcia
    Escoda, L.
    Ferrer, S.
    Monzo, E.
    Gonzalez, Y.
    de la Serna, J.
    Abrisqueta, P.
    Gine, E.
    Salamero, O.
    Montserrat, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 194 - 194
  • [32] Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
    Short, Nicholas James
    Keating, Michael J.
    Wierda, William G.
    Faderl, Stefan
    Ferrajoli, Alessandra
    Estrov, Zeev
    Smith, Susan C.
    O'Brien, Susan Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia
    Dartigeas, Caroline
    Van Den Neste, Eric
    Berthou, Christian
    Maisonneuve, Herve
    Lepretre, Stephane
    Dilhuydy, Marie-Sarah
    Bene, Marie-Christine
    Nguyen-Khac, Florence
    Letestu, Remi
    Cymbalista, Florence
    De Guibert, Sophie
    Aurran, Therese
    Laribi, Kamel
    Vilque, Jean-Pierre
    Tournilhac, Olivier
    Delmer, Alain
    Feugier, Pierre
    Cazin, Bruno
    Michallet, Anne-Sophie
    Levy, Vincent
    Troussard, Xavier
    Delepine, Roselyne
    Tavernier, Elsa
    Colombat, Philippe
    Leblond, Veronique
    LEUKEMIA & LYMPHOMA, 2016, 57 (02) : 328 - 334
  • [34] Life after Fludarabine, Cyclophosphamide, & Rituximab (FCR) - the Clinical Outcome of Patients with Chronic Lymphocytic Leukemia Who Receive Salvage Treatment after Frontline FCR
    Tam, Constantine S.
    Wierda, William G.
    O'Brien, Susan
    Lerner, Susan
    Khouri, Issa F.
    Kantarjian, Hagop M.
    Keating, Michael J.
    BLOOD, 2008, 112 (11) : 727 - 727
  • [35] Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia
    Gozzetti, Alessandro
    Candi, Veronica
    Fabbri, Alberto
    Schiattone, Luana
    Cencini, Emanuele
    Lauria, Francesco
    Frasconi, Adele
    Crupi, Rosaria
    Raspadori, Donatella
    Papini, Giulia
    Defina, Marzia
    Bartalucci, Giulia
    Bocchia, Monica
    LEUKEMIA RESEARCH, 2014, 38 (08) : 891 - 895
  • [36] Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
    Flinn, Ian W.
    Berdeja, Jesus G.
    Waselenko, Jamie K.
    Cooper, R. Seth
    Bi, Jia
    Shih, Kent
    Doss, Habib H.
    Dickson, Natalie
    Thompson, Dana S.
    Burris, Howard A., III
    Hainsworth, John D.
    BLOOD, 2010, 116 (21) : 1022 - 1022
  • [37] Comparison of fludarabine (F), cyclophosphamide (C), and rituximab (R) versus FCR plus bevacizumab (B) in relapse chronic lymphocytic leukemia (CLL)
    Lee, Hun Ju
    Wierda, William G.
    Ferrajoli, Alessandra
    Burger, Jan Andreas
    Trinh, Long
    Lerner, Susan
    Keating, Michael J.
    O'Brien, Susan Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
    Keating, MJ
    O'Brien, S
    Albitar, M
    Lerner, S
    Plunkett, W
    Giles, F
    Andreeff, M
    Cortes, J
    Faderl, S
    Thomas, D
    Koller, C
    Wierda, W
    Detry, MA
    Lynn, A
    Kantarjian, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4079 - 4088
  • [39] LOW DOSE ORAL FLUDARABINE PLUS CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH UNTREATED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (RETROSPECTIVE STUDY)
    Ionita, H.
    Ionita, I.
    Nicola, D. E.
    Pacurar, R.
    Ionita, C. O.
    Cheveresan, M.
    Borzak, G.
    Ionita, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 523 - 524
  • [40] Early versus deferred treatment with combined fludarabine, cyclophosphamide and rituximab (FCR) improves event-free survival in patients with high-risk Binet stage A chronic lymphocytic leukemia (CLL)
    Mueller, C.
    Cymbalista, F.
    Schweighofer, C.
    Busch, R.
    Porcher, R.
    Langerbeins, P.
    Cazin, B.
    Fink, A. -M.
    Dreyfus, B.
    Ibach, S.
    Lepretre, S.
    Fischer, K.
    Vehling-Kaiser, U.
    Eichhorst, B.
    Bergmann, M. A.
    Wendtner, C. -M.
    Stilgenbauer, S.
    Doehner, H.
    Leblond, V.
    Hallek, M.
    Levy, V.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 184 - 184
12345